Integra LifeSciences Holdings Corporation (IART) Shares Bought by American International Group Inc.

American International Group Inc. grew its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 6.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,997 shares of the life sciences company’s stock after buying an additional 2,994 shares during the quarter. American International Group Inc. owned 0.06% of Integra LifeSciences worth $2,473,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of Integra LifeSciences by 6.2% during the 2nd quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after buying an additional 468,678 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Integra LifeSciences by 227.0% during the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after buying an additional 2,705,488 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Integra LifeSciences during the 2nd quarter valued at approximately $112,068,000. Eagle Asset Management Inc. boosted its stake in shares of Integra LifeSciences by 39.0% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock valued at $89,778,000 after buying an additional 461,977 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Integra LifeSciences by 5.2% during the 2nd quarter. State Street Corp now owns 1,575,125 shares of the life sciences company’s stock valued at $85,860,000 after buying an additional 78,082 shares during the last quarter. Institutional investors own 87.62% of the company’s stock.

Integra LifeSciences Holdings Corporation (IART) opened at $48.92 on Friday. Integra LifeSciences Holdings Corporation has a one year low of $38.91 and a one year high of $56.42. The stock has a market capitalization of $3,839.09, a price-to-earnings ratio of 27.03, a P/E/G ratio of 2.15 and a beta of 0.65. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences had a return on equity of 16.35% and a net margin of 4.52%. The firm had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. During the same quarter last year, the business earned $0.93 earnings per share. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. analysts predict that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current fiscal year.

Several equities analysts have recently commented on the company. Royal Bank Of Canada reiterated a “sector perform” rating and set a $50.00 target price (up from $48.00) on shares of Integra LifeSciences in a research note on Thursday, November 9th. UBS reiterated a “buy” rating and set a $57.00 target price on shares of Integra LifeSciences in a research note on Tuesday, October 31st. Wells Fargo & Company cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Sunday, October 29th. Jefferies Group restated a “buy” rating and set a $56.00 price objective on shares of Integra LifeSciences in a research note on Sunday, October 29th. Finally, TheStreet cut Integra LifeSciences from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Integra LifeSciences currently has a consensus rating of “Buy” and a consensus price target of $53.82.

In related news, Director Barbara B. Hill bought 10,768 shares of the business’s stock in a transaction on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the purchase, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the sale, the vice president now owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.

WARNING: “Integra LifeSciences Holdings Corporation (IART) Shares Bought by American International Group Inc.” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/10/integra-lifesciences-holdings-corporation-iart-shares-bought-by-american-international-group-inc.html.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply